Zobrazeno 1 - 10
of 199
pro vyhledávání: ''
Autor:
Sabine Schmatloch, Sabine Seiler, G. Doering, Rita K. Schmutzler, Andrea Stefek, Eric Hahnen, C. Jackisch, S. Loibl, Arbeitsgemeinschaft Gynäkologische Onkologie Breast, Fenja Seither, Wolfgang D. Schmitt, Nicole Burchardi, J Huober, J-U Blohmer, Knut Engels, Peter Klare, PA Fasching, Carsten Denkert, Theresa Link, Michael Untch, Andreas Schneeweiss, Claus Hanusch, Jan Hauke, Kerstin Rhiem, Christoph Uleer
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(1)
Background The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA
Autor:
Jeffrey E. Gershenwald, H.A. Tawbi, Robert V. Rawson, Jing Ning, Michael T. Tetzlaff, K.A. Vu, C. Adhikari, Michael A. Davies, Lauren E. Haydu, Jennifer A. Wargo, Robyn P. M. Saw, Rodabe N. Amaria, Junsheng Ma, Serigne Lo, Alexander M. Menzies, Andrew J. Spillane, James S. Wilmott, Peter M. Ferguson, Richard A. Scolyer, Georgina V. Long, Merrick I. Ross
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(11)
Background Recent clinical trials demonstrated the safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete path
Autor:
Marc Peeters, Eric Baudin, David J. Gross, Maurizio Voi, James C. Yao, Kjell Öberg, Nicolas Rouyrre, Marianne Pavel, John D. Hainsworth
Publikováno v:
Ann Oncol
Annals of oncology
Annals of oncology
Background: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival versus placebo plus octreotide LAR among patients with advanced neuroendocrine tu
Autor:
John Simes, Val Gebski, Stephen P. Ackland, D.I. Watson, A. Barbour, Elizabeth H Barnes, Andrew Barbour, Christos S. Karapetis, Chris Karapetis, Gregory L. Falk, M. Oostendorp, Kate Wilson, M. Burge, Euan Walpole, Gavin Marx, L. Barnes, J. Shannon, David I. Watson, Bernard Mark Smithers, Louise M. Nott, Gang Tao Mai, Suresh C Varma, Tao Mai, R. Finch, Janine Thomas, E.T. Walpole, Guy Lampe, Jarad Martin, John Zalcberg
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(2)
Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histological response rates5%. We investigated whether tailoring neoadjuvant therapy can im
Autor:
Arndt Vogel, Arno Schad, M.P. Lutz, Peter C. Thuss-Patience, Markus Moehler, Florian Lordick, Sylvie Lorenzen, E. Van Cutsem, S.-E. Al-Batran, Maria Alsina, Baruch Brenner, Julia Slotta-Huspenina, Annett Maderer, Wolfgang Eisterer, Kersten Borchert, Lothar Mueller, Richard Greil, Johannes Meiler, R.D. Hofheinz, Thomas J. Ettrich
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(2)
Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in ad
Autor:
Silvana Leo, A. Rinaldi, Francesco Giuliani, Salvatore Pisconti, R. Esposito Abate, Alessia Iannaccone, Fortunato Ciardiello, Matilde Lambiase, Anna Maria Rachiglio, Evaristo Maiello, E. Martinelli, Nicola Normanno, M. Biglietto, Laura Forgione, Teresa Troiani, Tiziana Latiano, Roberto Bordonaro, Claudia Cardone, D. Rizzi, Alessandra Sacco
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(1)
Background Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information is available on the predictive role of liquid biopsy RAS testing in patients treated with first-line anti-EGFR
Autor:
Akira Mitsuhashi, Hideki Hanaoka, Makio Shozu, Yasunori Sato, Masaya Koshizaka, Takako Kiyokawa
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(2)
Background Metformin, widely used in the treatment of type 2 diabetes mellitus, reduces the risk of cancer and relapse after treatment. Fertility-sparing treatment for endometrial cancer (EC) with progestin is associated with a high chance of disease
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 26(6)
BACKGROUND To examine the association between hypertension (HTN), angiotensin system inhibitors (ASI) use and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). METHODS We retrospectively reviewed a
Autor:
Wolf O. Bechstein, Tanja Trarbach, Thomas Gruenberger, Florian Lordick, Jan Stoehlmacher-Williams, Anke Rentsch, Gunnar Folprecht, Torsten Liersch, Juergen Weitz, Dirk Jaeger, C.-H. Köhne, Hans-Rudolf Raab, U. Steger, Hauke Lang, Detlev Ockert, T. Suedhoff, Joerg T. Hartmann
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(5)
BACKGROUND Initially, unresectable colorectal liver metastases can be resected after response to chemotherapy. While cetuximab has been shown to increase response and resection rates, the survival outcome for this conversion strategy needs further ev
Autor:
Ronald E. Kates, J. Dünnebacke, O Gluz, U. Nitz, V Runde, Toralf Reimer, John Hackmann, N. Belzl, C. Oberhoff, Doris Augustin, Claudia Schumacher, I. Zuna, Nadia Harbeck, Christoph Uleer, M. Warm
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(1)
Background: WSG-ARA plus trial evaluated the effect of adjuvant darbepoetin alfa (DA) on outcome in node positive primary breast cancer (BC). Patients and methods: One thousand two hundred thirty-four patients were randomized to chemotherapy either w